ArticleScientific reports2020
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- LOW-NICKEL DIET AS A STRATEGY IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION.Arquivos de gastroenterologia · 2025Trial
- Persistence ofJournal of clinical medicine · 2026Article
- Improving Helicobacter pylori Treatment Standards: A Quality Improvement Project Against Maastricht VI Guidelines.Cureus · 2025Article
- Burden of Helicobacter pylori in Duodenal Ulcer Disease: Evidence From a Tertiary Hospital in Chennai, India.Cureus · 2025Article
- Novel therapeutic regimens againstFrontiers in microbiology · 2024Review
- Performing the ABC Method Twice for Gastric Cancer Risk Stratification: A Retrospective Study Based on Data from a Large-Scale Screening Facility.Diagnostics (Basel, Switzerland) · 2023Article
- Seven-day vonoprazan-based triple therapy as first-lineJGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Role of AlgC and GalU in the Intrinsic Antibiotic Resistance ofInfection and drug resistance · 2023Article
- Short-term outcomes and intermediate-term follow-up ofBMJ open · 2022Observational
- Factors Affecting the Intraluminal Therapy forMicroorganisms · 2022Article
- Study of Acid-related Disorders: Real-world Physician and Patient Perspectives on Burden ofGastro hep advances · 2022Article
- The Emergence of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Review
- Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients withJournal of clinical medicine · 2021Article
- Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation.Scientific reports · 2021Article
- Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice.Cureus · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eradication rate of Helicobacter pylori (H. pylori) has been decreasing every year, mainly due to the increase in antibiotic resistance. In fact, many other factors may affect H. pylori eradication. To analyze the clinical factors affecting the initial eradication therapy in Chinese patients with H. pylori infection. We conducted a retrospective study on 264 outpatients who were diagnosed with H. pylori-associated chronic gastritis and peptic ulcer disease between January and December 2015 at a large tertiary hospital in China. The patients were divided into three groups: ECA, RCA, and RCM (R: 20 mg rabeprazole, E: 40 mg esomeprazole, C: 0.5 g clarithromycin, A: 1.0 g amoxicillin and M: 0.4 g metronidazole). The patients were treated for 14 days and followed up for 1 year. The 14C-urea breath test (14C-UBT) was performed 4 weeks after the completion of the eradication therapy. The eradication rate was higher in ≥ 40-year-old patients than in < 40-year-old-patients (85.7% vs. 54.7%, p = 0.002). Multivariate analyses revealed only age ≥ 40 years to be significantly associated with a high H. pylori eradication rate [odds ratio (OR) 4.58, p = 0.003]. The H. pylori eradication rate in patients with duodenal ulcers was significantly higher than that in patients with gastric ulcers (79% vs. 60%, p = 0.012). Age could be a predictor of successful H. pylori eradication. Patients with duodenal ulcers had a higher H. pylori eradication rate than those with other lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.